secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001213900-24-000999
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned
--------------------------------------------------------------------------------

- REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.
- REL-1017 Phase 3 study 304 (Relight) enrollment to complete by year-end 2024, also ~300 patients.
- Phase 1 trial of modified-release psilocybin (REL-P11) in obese patients with steatotic liver disease to start H1 2024; Phase 2a data expected H1 2025.
- Dr. Cedric O'Gorman steps down as CMO; Dr. Andrew Cutler appointed Senior Clinical Development Advisor to support NDA process.
- Cash runway expected to extend beyond all 2024 catalysts; no specific cash balance disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/0001213900-24-000999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024000999/ea191114-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-000999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer